bioRxiv · 18 Nov 2026
CD38-NAMPT-p21 signaling promotes stress adaptation in CLL
BING HANh-index 3, Claudia CS Chini, GINA CICCIO LOPEZ, YUKI HAMADA, ANEEL PAULUS, ASHER CHANAN-KHAN, ESTEBAN BRAGGIO, ANDERS BERGLUND, Eduardo Nunes Chini
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States, accounting for ~30% of new diagnoses and ~4,000 deaths annually. High CD38 expression is a well-established marker of poor prognosis, yet the mechanistic basis of CD38-mediated treatment failure has remained incompletely understood. Here, we demonstrate that CD38 functions not merely as a prognostic biomarker but as a metabolic and signaling regulator that equips CLL cells to withstand cytotoxic and hypoxic stress. Using MEC-1 cells engineered to express CD38, we identified a CD38-NAMPT-p21 survival axis that confers resistance to fludarabine and hypoxia. CD38 NADase activity promoted NAMPT upregulation and AKT activation and was associated with accumulation of cytoplasmic p21. This CD38-dependent phenotype was lost in cells expressing a catalytically inactive CD38 mutant and was also reversed by pharmacologic inhibition of NAMPT (FK866) or suppression of p21 (UC2288). Analysis of three independent single-cell RNA-sequencing datasets of primary CLL further showed that naturally occurring CD38-positive CLL cells exhibit increased NAMPT expression and related stress-response signaling. Analysis of larger primary CLL cohorts further linked NAMPT expression to AKT and hypoxia signatures, providing additional support for the relevance of this pathway in patient-derived CLL. Together, these findings identify CD38-NAMPT-p21 signaling as an important mechanism of stress adaptation in CLL and suggest that targeting NAD⁺ metabolism and p21-mediated survival pathways may represent a potential strategy for CD38-high disease.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- BING HAN has the highest h-index among the authors (3).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.